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Abstract Introduction: High levels of amyloid b (Ab) are associated with cognitive decline in cognitively
normal (CN) older adults. This study investigated the nature of cognitive decline in healthy individ-
uals who did not progress to mild cognitive impairment or dementia.
Method: Cognition was measured over 72 months and compared between low (Ab2) and high
(Ab1) CN older adults (n 5 335) who did not progress to mild cognitive impairment or dementia
and who remained free of severe or uncontrolled systemic illness.
Results: Compared to the Ab2 group, the Ab1 group showed no cognitive impairment at baseline
but showed substantial decline in verbal learning, episodic memory, and attention over 72 months.
Discussion: Moderate cognitive decline, particularly for learning and memory, was associated with
Ab1 in CN older adults in the absence of clinical disease progression and uncontrolled or serious
comorbid illness.
 2017 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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1. Background
The preclinical phase of Alzheimer’s disease (AD) is char-
acterized by the presence of abnormal levels of amyloid b
(Ab1) and progressive cognitive decline in otherwise healthy
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older adults [1]. There is growing emphasis on the preclinical
phase of AD as a starting point for clinical trials of anti-
amyloid agents with the goal of halting the disease before
the development of clinical symptoms [2]. Although it is
recognized that cognitive decline in preclinical AD most
likely reflects multiple biological changes, studies and clin-
ical trials often require only Ab1 for the classification of pre-
clinical AD. In this context, developing accurate estimates of
Ab1-related cognitive change in cognitively normal (CN)
older adults is essential. However, the precise nature and
magnitude of Ab1-related cognitive decline differs between
studies [3–6]. One possible reason for this difference is that
neuropsychological study of preclinical AD has more in
common with the study of aging than the study of
dementia. Thus, issues known to influence or inflate
estimates of age-related cognitive change in CN older adults
might also increase the estimates of Ab1-related cognitive
decline in preclinical AD [7,8].
One factor that may influence estimates of Ab1-related
cognitive decline is progression from preclinical AD to a
clinical disease stage (i.e., mild cognitive impairment
[MCI] or dementia). Although studies of preclinical AD
exclude individuals who meet clinical criteria for MCI or de-
mentia at enrollment or baseline assessment, rates of clinical
disease progression during prospective studies are consis-
tently large (e.g., 10.8% in Australian Imaging Biomarkers
and Lifestyle [AIBL] [3], 10% in Knight Alzheimer’s Dis-
ease Research Centre [Knight ADRC] [9], 7.7% in Alz-
heimer’s Disease Neuroimaging Initiative [ADNI] [10],
and 6.1% in Mayo Clinic Study of Aging samples [11]). Es-
timates of Ab1-related cognitive decline derived from sam-
ples that include high rates of clinical disease progression
might therefore be inflated. When assessed on a single occa-
sion, CN Ab1 adults generally show no cognitive impair-
ment relative to matched Ab2 adults [12–14]. Thus, it is
possible that in the absence of any clinical disease
progression, Ab1 might be associated with only small, or
even no, cognitive decline in CN older adults.
The inclusion of individuals with severe or uncontrolled
systemic illnesses in study samplesmay also inflate estimates
of Ab1-related cognitive decline. In older adults, systemic
illnesses, such as diabetes mellitus or hypertension, show
increased prevalence and are associatedwith subtle cognitive
impairment [15,16]. Given their high prevalence in aging,
epidemiological studies of preclinical AD include large
proportions of individuals with these systemic illnesses
[17]. In addition, the published criteria formost experimental
samples do not specify whether such conditions have been
excluded or state these are excluded only if they prevent lon-
gitudinal assessment (e.g., ADNI or Knight ADRC
[5,10,18]). As such, inclusion of older adults with systemic
illness in studies of preclinical AD may have led to inflated
estimates of Ab1-related cognitive decline.
Finally, the accuracy of estimates of Ab1-related cogni-
tive decline might be reduced by the use of neuropsycholog-
ical tests that are not appropriate for use with CN older
adults. Many studies of preclinical AD use neuropsycholog-
ical tests selected for their sensitivity to the substantial
cognitive impairment associated with dementia (e.g., Clock
Drawing, Boston Naming Test, or Mini–Mental Status
Examination [MMSE] [4,10,19,20]). When such tests are
applied in CN samples, the resulting data distributions are
often characterized by negative skew, ceiling effects, and
restriction of range [21–23]. Consequently, random error is
biased toward the negative end of measurement scales
inflating estimates of cognitive decline [24].
To obtain unbiased estimates of Ab1-related cognitive
decline, appropriate neuropsychological tests should be
applied prospectively to Ab1 CN adults, who do not progress
to clinicalADduring the study period, andwhodonot have se-
vere systemic illness. In other neuropsychological contexts,
samples that exclude data fromindividualswho latermeet clin-
ical criteria for cognitive impairment or dementia are defined
as robust samples [25].Groupmeanperformance onneuropsy-
chological tests in robust samples is generally superior and has
reduced variability compared with estimates from conven-
tional normative samples [26,27]. Therefore, application of
the neuropsychological robust sample method may provide
more accurate estimates of the nature and magnitude of
Ab1-related cognitive decline in preclinical AD.
The aim of this study was to determine the nature and
magnitude of Ab1-related cognitive decline and impair-
ment, in the absence of clinical disease progression and other
illnesses, such as systemic illness, that are associated with
older age. Although Ab1 is unlikely to be the sole causative
factor for cognitive decline and likely interacts with other
markers of AD, such as tau and neurodegeneration, it is
necessary for the classification of preclinical AD and has
been shown to be a strong predictor of cognitive decline.
By developing accurate estimates of Ab1-related cognitive
decline, a solid framework can be established to then further
investigate the contribution of other factors. It was hypothe-
sized that theAb1CNolder adults would show subtle cogni-
tive decline relative to the Ab2 CN older adults. The second
hypothesis was that Ab1 CN older adults would show no
cognitive impairment relative to the Ab2 CN older adults.
2. Method
2.1. Participants
Participants were recruited from the AIBL study incep-
tion cohort (Fig. 1 summarizes the method used to select par-
ticipants). The AIBL sample and methodology have been
described in detail previously [28]. The AIBL study was
approved by three institutional research and ethics commit-
tees (St Vincent’s Health, Austin Health, and Edith Cowan
University). All participants provided written informed con-
sent before participating in the study. Exclusion criteria
included a history of non-AD dementia, Parkinson’s disease,
schizophrenia, bipolar disorder, cancer (other than basal skin
carcinoma) within the last 2 years, uncontrolled diabetes,
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current depression (indicated by a Geriatric Depression
Scale score .5), or current regular alcohol consumption
exceeding two standard drinks per day for women or four
per day for men according to recommended consumption
levels from the Australian Alcohol Guidelines [29].
The current health status of participants at baseline was
also reviewed. All participants were determined to have no,
or only subclinical and medically well controlled, systemic
or neurological illness on the basis of a medical examination
including measurement of vital signs (height, weight, blood
pressure, and abdominal circumference), blood pathology,
and medical history. Participants who later withdrew from
theAIBL study for reasons of ill health (e.g., cancer or stroke)
were also excluded from the current analyses.
The sample included 335 CN older adults aged between
60 and 85 years. All participants had undergone positron
emission tomography neuroimaging with an Ab tracer and
at least two clinical and neuropsychological assessments
(mean number of follow-up assessments 4.81, with 88.1%
of participants completing all 5 assessments) within
72 months. Included participants also scored above 24 on
the MMSE at baseline and did not meet criteria for MCI
[30] or dementia [31] at any follow-up assessment.
2.2. Measures
2.2.1. Neuroimaging
Participants underwent positron emission tomography
neuroimaging on a separate day to their clinical and neuro-
psychological assessment. Where multiple scan results
were available, Ab status was determined from the first
scan (n 5 109 at baseline, n 5 17 at 18 months, n 5 134
at 36months, n5 63 at 54months, and n5 12 at 72months).
Participants were administered either 11C-Pittsburgh
compound-B (PiB; n 5 174), 18F-florbetapir (FBP;
n 5 72), or 18F-flutemetamol (FLUTE; n 5 89), and then
standardized uptake value (SUV) data were acquired 40 to
70, 50 to 70, or 90 to 110minutes after injection, respectively.
Data were then summed and normalized to obtain the SUV
ratio (SUVR) using the cerebellar cortex as reference region
for PiB, the whole cerebellum for FBP, and the pons for
FLUTE [32,33]. A linear regression transformation was
then applied to the SUVR scores for FBP and FLUTE to
transform them into a “PiB-like” SUVR unit termed
“Before the Centiloid Kernel Transformation” [33]. These
procedures have been described in greater detail previously
[32,33].
2.2.2. Demographics
Age and gender were self-reported. Depression and anx-
iety symptoms were assessed by the Hospital Anxiety and
Depression Scale (HADS [34]). The Wechsler Test of Adult
Reading (WTAR [35]) was administered to estimate intelli-
gence quotient.
2.2.3. Neuropsychological assessment
TheAIBL neuropsychological test battery and procedures
for administration have been described previously [28]. The
present study used a subset of the AIBL battery selected spe-
cifically because they provided normal data distributions,
had a high test-retest reliability, and were sensitive to cogni-
tive changes associated with healthy aging [23] (Table 1).
The selected tests included measures of learning, immediate
and delayed recall aspects of episodic memory, psychomotor
speed, attention, and executive function.
3. Procedure
Participants fasted overnight before attending the
research facility in the morning. Written consent was ob-
tained. An 80-ml blood sample was then drawn and sent
Fig. 1. Sample screening process. Abbreviation: MCI, mild cognitive impairment.
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for genotyping and clinical pathology testing. Participants
were provided breakfast while they completed self-report
questionnaires on demographics, mood, and medical history.
Finally, trained research assistants conducted a clinical inter-
view and neuropsychological assessment and assessed vital
signs in a single 120-minute session according to standard-
ized protocols.
4. Data coding
Neuroimaging results were classified as Ab1 or Ab2 to
create a single-dichotomous categorical variable. Ab1 was
classified according to an SUVR/Before the Centiloid
Kernel Transformation threshold of 1.5 [33]. Individuals
were also classified as to whether they carried an apolipopro-
tein E ε4 (APOE) ε4 allele, and this was also coded as a
single-dichotomous categorical variable. Only three APOE
ε4 homozygotes were included in this group.
5. Data screening and analysis
All analyses were conducted using Statistical Package for
Social Sciences (SPSS), version 23.0 and R statistical
computing packages.
Data frequency distributions were generated for each
outcome measure and inspected to identify outlier data
points beyond 1.5 times the interquartile range. These data
points were excluded from analyses. Visual inspection of
data frequency distributions indicated diversion from
normality for MMSE, Wechsler Test of Adult Reading,
HADS-D, and HADS-A. Nonparametric testing was used
for these variables.
First, independent-sample t-tests were used to compare
the Ab2 and Ab1 groups on demographic and clinical char-
acteristics. Where outcome data were not normally distrib-
uted, a Mann-Whitney U test was used to compare the
groups, or where data were categorical, a c2 test was used.
Second, a series of linear mixed model analyses were
conducted to model the rate of change over time in cognitive
function for each of the Ab groups. Ab group, time (base-
line, 18, 36, 54, and 72 months), and the time! Ab group
interaction were entered as fixed factors; participants and
time as random factors; and performance on each of the neu-
ropsychological tests as the dependent variable. Age and
APOE ε4 status were included as covariates to account for
their potential to influence cognitive performance in CN
older adults. Cohen’s d effect size measure of standardized
mean difference was then calculated to determine the magni-
tude of the difference in rate of change in cognitive function
between Ab groups.
Third, a series of one-way analysis of covariance were
used to determine the impact of Ab on each cognitive test
at the baseline assessment. Ab group was entered as a factor,
age andAPOE ε4 status as covariates and the baseline perfor-
mance on each of the neuropsychological tests as the depen-
dent variable. Cohen’s d effect size measure of standardized
mean difference was then calculated to determine the magni-
tude of the difference in performance between Ab groups.
Statistical significance for all comparisons was set to
P , .05 level. As performance on the cognitive measures
used in the present study was likely to be correlated, strict
adjustment of error rates using Bonferroni criteria would
be overly conservative. In addition, inspection of estimates
of effect size that were generated for each comparison was
used to guide interpretation of results and minimize Type I
error. Group differences or associations were only inter-
preted where they were statistically significant, and esti-
mates of effect sizes were nontrivial (i.e., d . 0.2 [43]).
Table 1
Summary of the neuropsychological test battery and their outcome measures
Cognitive domain Neuropsychological test Outcome Reference
Processing speed and attention Digit Symbol Coding* Number of items correctly coded within 2 minutes [36]
Stroop Words Seconds to complete trial [37]
Detection Speed (log10 milliseconds) [38]
Identification Speed (log10 milliseconds) [38]
Executive Function Digit Span* Total correct trials (forwards and backwards) [36]
Letter Fluency (FAS) Number of words produced [39]
Category Fluency (animals and boys names) Number of words produced [39]
Category Fluency (fruit and furniture) Number of words produced while switching categories [39]
One Back Speed (log10 milliseconds) [38]
Learning and Immediate Recall Logical Memory 1y Number of elements correctly recalled [40]
CVLT-II trials 1–5 Number of words correctly recalled [41]
RCFT Short Delay Number of elements correctly drawn [42]
One Card Learning Accuracy (arcsine proportion correct) [38]
Delayed Recall Logical Memory 2y Number of elements correctly recalled [40]
CVLT-II Long Delay Number of words correctly recalled [41]
RCFT Long Delay Number of elements correctly drawn [42]
Abbreviations: CVLT-II, California Verbal Learning Test-Second edition; RCFT, Rey Complex Figure Test; WAIS-III, Wechsler Adult Intelligence Scale–
Third Edition.
*Subtest of the WAIS-III.
yStory A only, subtest of the Wechsler Memory Scale–Revised.
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6. Results
6.1. Sample characteristics
Demographic and clinical characteristics of the total sam-
ple and each Ab group are summarized in Table 2. Overall,
the total sample had slightly more females than males,
median-estimated intelligence quotient was in the average
range, symptoms of depression and anxiety were reported
to be low, and vital signs were within subclinical ranges.
The Ab1 group was slightly older and had a higher propor-
tion of APOE ε4 carriers than the Ab2 group. No other dif-
ferences between groups were observed.
6.2. Effect of Ab on cognitive decline
Mean slopes and standard deviation of performance over
72 months for each Ab group are shown in Table 3. Linear
mixed model analysis indicated significant Ab
group! time interactions for performance on the identifica-
tion, Logical Memory 1 and 2, California Verbal Learning
Test-Second edition trials 1–5 and Long Delay, and One
Card Learning tasks (Table 3). Each of these analyses indi-
cated that the Ab1 group declined faster over 72 months
than the Ab2 group, and differences in rate of change
were small to moderate in magnitude (Cohen’s d 5 20.31
to 20.50; Fig. 2). No difference in rate of change of cogni-
tive performance was observed between groups for Digit
Symbol, Stroop Words, Detection, Digit Span, Letter
Fluency (FAS), Category Fluency (animals and boys
names), Category Fluency (fruit and furniture), One Back,
and Rey Complex Figure Test Short or Long Delay.
6.3. Effect of Ab on cognitive impairment
Group means and standard deviations for baseline perfor-
mance on the neuropsychological tests are shown in Table 4.
There was a small difference (d 5 0.28) in performance be-
tween the Ab groups on the Identification task, with the
Ab1 group showing faster mean response times than the
Ab2 group. There were no significant differences in perfor-
mance between the Ab groups on any other neuropsycholog-
ical test. Fig. 3 shows the magnitude of the difference in
performance between groups on each test, which was uni-
formly trivial to small (Cohen’s d 5 0.01 to 0.28).
To account for the potential influence of baseline differ-
ence in performance on the Identification task in rate of
change on the task, the longitudinal model was rerun adding
baseline performance as a covariate. After adjusting for
baseline performance, the Ab group! time interaction re-
mained statistically significant and the magnitude of differ-
ence in rate of change remained small (d 5 0.38).
7. Discussion
The hypothesis that in Ab1 CN older adults, who do not
progress to MCI or dementia over 72 months and who have
no severe or uncontrolled systemic illness, would show sub-
tle cognitive decline relative to Ab2 CN adults was sup-
ported partially. Relative to the Ab2 group, the Ab1
group showed decline over 72 months in verbal learning,
episodic memory, and attention. Despite the exclusion of in-
dividuals whose disease had progressed to MCI or dementia,
Ab1-associated cognitive decline was small to moderate in
magnitude (e.g., Cohen’s d between20.31 and20.50; sum-
marized in Fig. 2) with the greatest decline observed for ver-
bal episodic memory. These estimates of Ab1-related
memory decline accord with estimates from recent meta-
analyses of cognitive decline in preclinical AD, which found
Ab1 was associated with small to moderate cognitive
decline (Cohen’s d between 20.24 and 20.30) over an
average of 5 years [6]. They also support brain-behavior
Table 2
Demographic and clinical assessment means (SD) for total sample and each Ab group at baseline assessment
Demographic and clinical characteristic
Total Ab2 Ab1
PMean (SD) Mean (SD) Mean (SD)
N 335 277 58
%Female 57.9 58.5 55.2 .64
%APOE ε4 carrier 25.1 19.5 35.7 .00
Age 68.28 (5.71) 67.62 (5.36) 71.43 (6.26) .00
MMSE* 29 (5) 29 (5) 29 (4) .49
Estimated IQ (WTAR)* 114 (35) 114 (35) 114 (27) .13
HADS Depression* 2 (14) 2 (11) 2 (14) .87
HADS Anxiety* 4 (15) 4 (12) 4 (15) .98
Systolic BP 136.52 (14.24) 136.11 (14.56) 138.58 (12.39) .20
Diastolic BP 78.42 (9.23) 78.13 (9.52) 79.89 (7.51) .21
Heart Rate 67.05 (9.26) 66.84 (9.33) 68.06 (8.97) .38
Abdominal Circumference 91.40 (12.56) 91.45 (12.81) 91.15 (11.29) .88
Body Mass Index 26.36 (3.93) 26.47 (3.954) 25.84 (3.81) .28
Abbreviations: APOE, apolipoprotein E; BP, blood pressure; HADS, Hospital Anxiety and Depression Scale; IQ, intelligence quotient; MMSE,Mini–Mental
State Examination; SD, standard deviation; WTAR, Wechsler Test of Adult Reading.
NOTE. Bold data indicates statistical significance (P ,.05).
*Non-normal distribution–Mann-Whitney test, median and range reported.
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models of early AD, which propose that disruption to
episodic memory, due to the early predilection for Ab-
related cell death in the medial temporal lobes, is the earliest
clinical manifestation of AD [1].
Although themagnitude of the cognitive decline observed
in the current robust sample is consistent with that observed
previously [4,6,44], the nature of Ab1-related decline
observed here was qualitatively different. For example, in
the present study, Ab1-related decline was observed for
aspects of episodic memory, including verbal list learning,
visual pattern separation, and paragraph learning, as well
as for aspects of attention (Table 3). However, previous
studies report Ab1 to also be associated with decline in
global cognition, visuospatial function, and executive func-
tion [4,6,45,46]. Notably, the sample size of the present
study is similar or larger than that of previous studies
(excludingmeta-analyses), and the effect sizes for those tests
where there was an absence of significant Ab-related cogni-
tive declinewere predominantly trivial and small at best. This
suggests that a failure to detect Ab-related cognitive decline
on these measures was not due to insufficient statistical po-
wer. One possible reason for the absence of decline in these
same domains in this study may be that the neuropsycholog-
ical tests used had optimal psychometric properties for the
assessment of CN older adults. For example, in previous
studies, the use of tests that generate data distributions char-
acterized by skew or restricted range (e.g., Clock Drawing,
Boston Naming Test, or MMSE) may have resulted in
randomerror in the data distribution that is biased to the nega-
tive end of the measurement scale and consequently
increased group estimates of Ab1-related decline for those
measures [21,23,24].
Qualitative differences in Ab1-related cognitive decline
between this and previous studies may also be due to the
absence of any clinical disease progression in the current sam-
ple. Previous studies include a relatively high proportion (e.g.,
w10%) of individuals who progressed to clinical disease dur-
ing the study period. Pathological studies indicate that during
the earliest stages of AD, the hippocampus and entorhinal cor-
tex, which subserve episodic memory function, are most
affected [47]. However, as the disease progresses, the limbic
system and neocortex become involved [47]. Hence, the
absence of decline in executive and visuospatial function
may reflect thevery early stageof disease in the current sample.
Fig. 2. Ab-associated cognitive decline—magnitude of difference (Cohen’s
d) between the mean slope of the Ab1 group relative to the Ab2 group over
72 months. Negative Cohen’s d values indicate greater decline in function
over time for that measure in the Ab1 group comparedwith the Ab2 group.
Abbreviations: Animals Names, category fluency for animals and boys
names; CVLT-II, California Verbal Learning Test-Second edition; FAS, let-
ter fluency; Fruit Furniture Total, total Correct Responses for switching
category fluency for fruit and furniture; RCFT, Rey Complex Figure Test.
Table 3
Results of linear mixed model analyses covaried for age and APOE ε4 with mean (SD) slopes for each Ab group
Neuropsychological measure
Age APOE ε4 Ab status Time
Ab status!
time Ab2 Ab1
F P F P F P F P F P Slope (SD) Slope (SD)
Digit Symbol Coding 73.85 .00 2.86 .09 1.42 .23 3.36 .07 2.73 .10 0.54 (7.15) 21.22 (4.57)
Stroop Words 40.61 .00 1.36 .25 0.16 .69 0.01 .92 0.07 .79 0.12 (2.42) 0.02 (1.60)
Detection 3.78 .05 0.86 .35 1.99 .16 8.54 .00 1.04 .31 0.01 (0.10) 0.03 (0.06)
Identification 18.19 .00 3.73 .05 9.42 .00 23.89 .00 6.83 .01 0.00 (0.05) 0.02 (0.03)
Digit Span 2.18 .14 2.49 .12 1.76 .19 4.93 .03 1.03 .31 20.12 (2.13) 20.44 (1.42)
FAS 4.85 .03 2.25 .13 4.33 .04 0.10 .76 0.20 .66 0.60 (6.25) 0.18 (3.91)
Animals Names 20.41 .00 0.09 .76 3.07 .08 4.70 .03 2.03 .16 0.05 (4.99) 21.01 (3.26)
Fruit Furniture Total 36.22 .00 0.04 .85 0.01 .94 2.39 .12 0.04 .84 20.24 (2.09) 20.30 (1.41)
One Back 24.03 .00 5.32 .02 5.33 .02 2.41 .12 2.97 .09 20.01 (0.06) 0.01 (0.04)
Logical Memory 1 7.53 .01 0.61 .43 0.65 .42 5.40 .02 8.29 .00 0.54 (2.56) 20.55 (1.68)
CVLT-II 1–5 23.65 .00 1.58 .21 0.11 .74 2.85 .09 6.29 .01 1.64 (7.59) 21.19 (4.46)
RCFT Short Delay 16.64 .00 0.68 .41 1.04 .31 0.30 .58 2.62 .11 0.70 (3.67) 20.19 (2.41)
One Card Learning 9.20 .00 0.38 .54 6.66 .01 3.73 .05 3.88 .05 0.01 (0.10) 20.02 (0.06)
Logical Memory 2 6.39 .01 0.86 .36 1.11 .29 4.31 .04 8.54 .00 0.64 (2.64) 20.51 (1.67)
CVLT-II Long Delay 13.85 .00 1.48 .22 0.54 .46 10.32 .00 10.14 .00 0.31 (1.79) 20.53 (1.17)
RCFT Long Delay 20.51 .00 0.94 .33 2.51 .11 0.57 .45 3.02 .08 0.67 (3.53) 20.25 (2.43)
Abbreviations: Animals Names, category fluency for animals and boys names; CVLT-II, California Verbal Learning Test-Second edition; FAS, letter fluency;
Fruit Furniture Total, total Correct Responses for switching category fluency for fruit and furniture; RCFT, Rey Complex Figure Test; SD, standard deviation.
NOTE. Bold data indicates statistical significance (P ,.05).
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A third possibility is that the more diverse Ab1-related
cognitive decline observed in previous studies reflects the
presence of uncontrolled or severe systemic illness in these
samples. For example, epidemiological studies, such as the
Mayo Clinic Study of Aging, deliberately include high pro-
portions of individuals who have one or more systemic ill-
nesses due to their high prevalence in older adults [17].
Other experimental or natural history samples often do not
specify whether such conditions were excluded (e.g.,
ADNI or Knight ADRC [5,10]). Systemic illnesses are
prevalent in older adults and have been shown to be
associated with reduced cognitive function [15]. Given
this, it is possible that in prior studies such illnesses influ-
enced the nature of cognitive decline in preclinical AD.
The results of the present study highlight the potential of
the robust sample method for enhancing estimates of cogni-
tive decline and for examining changes occurring in the
earliest disease stages.
The second hypothesis that Ab1 CN older adults would
show no cognitive impairment relative to the Ab2 CN older
adults was partially supported. Consistent with prior studies,
there were no, or only small, significant differences in per-
formance observed between the Ab groups on the neuropsy-
chological tests [12–14]. Furthermore, effect sizes for the
group differences were uniformly trivial to small (Fig. 3),
indicating that the absence of statistically significant group
differences was not due to low statistical power. Although
meta-analytic investigations do suggest that Ab1 is ass-
ociated with a small to moderate cognitive impairment
(e.g., Cohen’s d 5 0.26 to 0.47) of global cognition, visuo-
spatial function, processing speed, executive function, and
episodic memory in CN older adults, none of the samples
submitted to meta-analyses could be considered robust
[6,48]. Thus, data from the present study suggest that
Ab1-associated cognitive impairment in CN older adults
may have been overestimated previously.
Although the results of the present study provide an
indication of the effect of Ab1 on cognitive function for
CN older adults, independent of systemic illness or pro-
gression to clinical AD, they should be interpreted in the
context of several limitations. The Ab status of a large pro-
portion of the sample (67.5%) was not able to be deter-
mined at baseline, as those participants did not undergo
neuroimaging until a later follow-up assessment. However,
given the relatively slow rate of accumulation of Ab in CN
individuals (e.g., mean increase of 0.02 in SUVR per year
[49]), it is unlikely that any individual who was identified
at Ab1 on the basis of a scan at follow-up would not have
also been Ab1 at baseline. In addition, the AIBL sample is
a convenience sample and as such may not be representa-
tive of the broader population of older adults in Australia
specifically, or developed countries more generally. This
is especially the case after exclusion of CN older adults
with severe or uncontrolled systemic illness. Related to
this, the application of the robust sampling method and
rigorous health criteria applied in the present study raises
the issue of whether such samples, particularly Ab2 CN
older adults, should be considered as representative of su-
per aging or successful aging rather than normal aging
[7,50]. However, in the absence of any clear
neuropsychological criteria for super or successful aging,
Fig. 3. Ab-associated cognitive impairment–magnitude of difference (Co-
hen’s d) between performance of Ab1 group relative to the Ab2 group
at baseline. Negative Cohen’s d values indicate worse performance on
that measure in the Ab1 group compared with the Ab2 group at the base-
line assessment. Abbreviations: Animals Names, category fluency for ani-
mals and boys names; CVLT-II, California Verbal Learning Test-Second
edition; FAS, letter fluency; Fruit Furniture Total, total Correct Responses
for switching category fluency for fruit and furniture; RCFT, Rey Complex
Figure Test.
Table 4
Baseline mean (SD) performance of each Ab group on the
neuropsychological tests and results of analysis of covariance with age and
APOE ε4 as covariates
Neuropsychological measure
Ab2 Ab1
F PMean (SD) Mean (SD)
Digit Symbol Coding 64.28 (12.53) 61.91 (15.60) 1.52 .22
Stroop Words 17.53 (4.08) 17.60 (5.07) 0.01 .91
Detection 2.52 (0.12) 2.51 (0.14) 0.17 .68
Identification 2.69 (0.06) 2.72 (0.08) 4.89 .03
Digit Span 18.64 (4.20) 17.91 (5.21) 1.31 .25
FAS 45.32 (12.19) 41.77 (15.17) 3.62 .06
Animals Names 43.47 (8.70) 41.09 (10.81) 3.18 .08
Fruit Furniture Total 13.91 (2.79) 14.32 (3.47) 0.89 .35
One Back 2.92 (0.09) 2.94 (0.11) 2.18 .14
Logical Memory 1 13.59 (3.90) 13.78 (4.85) 0.09 .76
CVLT-II 1–5 53.37 (10.24) 54.25 (12.74) 0.32 .57
RCFT Short Delay 18.10 (5.77) 17.28 (7.18) 0.85 .36
One Card Learning 1.04 (0.12) 1.03 (0.14) 0.55 .46
Logical Memory 2 12.55 (4.00) 12.36 (4.97) 0.10 .75
CVLT-II Long Delay 12.42 (3.00) 12.40 (3.74) 0.00 .96
RCFT Long Delay 18.47 (5.91) 17.12 (7.36) 2.22 .14
Abbreviations: Animals Names, category fluency for animals and boys
names; CVLT-II, California Verbal Learning Test-Second edition; FAS, let-
ter fluency; Fruit Furniture Total, total Correct Responses for switching
category fluency for fruit and furniture; RCFT, Rey Complex Figure Test;
SD, standard deviation.
NOTE. Bold data indicates statistical significance (P ,.05).
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this is not currently able to be determined. Although the
representativeness of this sample is limited, the data from
the study do show clearly that in the absence of more
advanced disease or comorbid illnesses, high Ab is
associated with moderate cognitive decline, but not
impairment, in CN older adults.
The cognitive decline observed in the present study may
be reflective of the influence of Ab on cognition, however,
may also be indicative of the interaction of Ab and other
factors. There is increasing emphasis on the importance
of the role of tau and other indicators of neurodegeneration
for predicting clinical disease progression and cognitive
decline in AD [3,11,51]. The aim of this study was not
to investigate these relationships, but rather to provide a
foundation for future investigations, by first establishing
accurate estimates of the relationship between Ab and
cognitive decline independent of clinical disease
progression and comorbid illness. It would be useful for
future studies to now consider the potential for tau or
neurodegeration markers to modify these estimates of
Ab1-related cognitive decline in robust samples of
healthy older adults.
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RESEARCH IN CONTEXT
1. Systematic review: The authors reviewed the litera-
ture using sources such as PubMed, MEDLINE,
and PsycINFO. There is consensus that elevated am-
yloid b (Ab1) is associated with cognitive decline in
healthy older adults, the nature and magnitude of this
varies between studies. This may be because preclin-
ical Alzheimer’s disease (AD) samples often include
individuals with comorbid medical illness or whose
disease progresses during the study period; both fac-
tors will increase estimates of cognitive decline.
These relevant studies are appropriately cited.
2. Interpretation: Moderate decline in attention,
learning, and memory occurred in the robust sample
of Ab1 cognitively normal older adults. This finding
confirms that Ab1 is sufficient to cause cognitive
decline in older adults.
3. Future directions: Future studies should investigate
Ab1-related cognitive decline in robust samples of
preclinical AD with specific comorbid systemic ill-
nesses, as well as interaction with other AD bio-
markers.
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